Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art .
Antidepressant activity of monoamine oxidase inhibitors ( MAOIs ) was initially noted in the 1950s , and by the early 1960s , they were a mainstay of antidepressant treatment .
Reports of adverse events such as acute hypertensive reactions following the ingestion of certain foods and beverages tempered clinicians' enthusiasm for MAOIs .
Introduction of the tricyclic antidepressants and the selective serotonin reuptake inhibitors led to declines in the use of MAOIs .
However , MAOIs have been well established as an effective intervention for people with treatment-resistant depression , and transdermal formulations may provide a valuable therapeutic option and eliminate the drug-food interaction .
